Divi's Laboratories Limited (DIVISLAB) — encumbrance
· NSE
Neutral
No summary available
About Divi's Laboratories Limited (DIVISLAB)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,79,470.03 Cr
P/E: 72.4
ROE: 16.6%
ROCE: 22.1%
Recent Announcements from Divi's Laboratories Limited
-
share transfer — 7 July 2026
Divi's Laboratories submitted a SEBI-mandated certificate from its share transfer agent KFin Technologies for the quarter ended June 30, 2026, confirm... -
🟡 Board Meeting — 11 June 2026
Divi's Laboratories announced a ₹30 per share dividend for FY2025-26, payable after August 14, 2026, to shareholders on record as of July 24, 2026, su... -
🔴 Financial Results — 23 May 2026
Divi's Laboratories announced that the audio recording of its Q4 FY26 earnings conference call held on May 23, 2026, is now available on its website u... -
🔴 Financial Results — 31 March 2026
Divi's Laboratories announced closure of its trading window effective April 1, 2026, ahead of audited financial results for the quarter and year ended... -
🔴 Announcement — 21 March 2026
Divi's Laboratories received a Draft Assessment Order from the Income Tax Authority for FY2022-23 proposing **₹570.51 crores** in additions/disallowan...
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when DIVISLAB files new disclosures
Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DIVISLAB — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research